- Home
- JHS vs CRDF Comparison
JHS vs CRDF Comparison
Compare JHS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- CRDF
- Stock Information
- Founded
- JHS 1973
- CRDF 1999
- Country
- JHS United States
- CRDF United States
- Employees
- JHS N/A
- CRDF N/A
- Industry
- JHS Finance Companies
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHS Finance
- CRDF Health Care
- Exchange
- JHS Nasdaq
- CRDF Nasdaq
- Market Cap
- JHS 131.4M
- CRDF 152.3M
- IPO Year
- JHS N/A
- CRDF N/A
- Fundamental
- Price
- JHS $11.56
- CRDF $2.35
- Analyst Decision
- JHS
- CRDF Strong Buy
- Analyst Count
- JHS 0
- CRDF 5
- Target Price
- JHS N/A
- CRDF $11.10
- AVG Volume (30 Days)
- JHS 32.8K
- CRDF 876.0K
- Earning Date
- JHS 01-01-0001
- CRDF 10-29-2025
- Dividend Yield
- JHS 3.96%
- CRDF N/A
- EPS Growth
- JHS N/A
- CRDF N/A
- EPS
- JHS 0.02
- CRDF N/A
- Revenue
- JHS N/A
- CRDF $545,000.00
- Revenue This Year
- JHS N/A
- CRDF N/A
- Revenue Next Year
- JHS N/A
- CRDF N/A
- P/E Ratio
- JHS $553.50
- CRDF N/A
- Revenue Growth
- JHS N/A
- CRDF N/A
- 52 Week Low
- JHS $9.76
- CRDF $1.90
- 52 Week High
- JHS $11.25
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- JHS 36.79
- CRDF 48.19
- Support Level
- JHS $11.54
- CRDF $2.10
- Resistance Level
- JHS $11.93
- CRDF $2.38
- Average True Range (ATR)
- JHS 0.14
- CRDF 0.10
- MACD
- JHS -0.04
- CRDF 0.00
- Stochastic Oscillator
- JHS 1.72
- CRDF 31.93
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.